New anthelmintics for livestock: the time is right
1Animal Health Laboratories, Department of Agriculture and Food Western Australia, Albany, WA 6330, Australia. bbesier@agric.wa.gov.au
Trends in Parasitology
|November 23, 2006
Summary
Anthelmintic resistance threatens small-ruminant enterprises globally. Developing new anthelmintics is crucial due to widespread drug resistance and limited non-chemical options, ensuring market viability and product longevity.
Area of Science:
- Veterinary Parasitology
- Anthelmintic Resistance
- Small Ruminant Health
Background:
- Increasing anthelmintic resistance poses a significant threat to the economic viability of small-ruminant farming operations.
- A lack of novel anthelmintic drug classes developed over recent decades, coupled with market skepticism from animal health companies, has exacerbated the problem.
Purpose of the Study:
- To highlight the urgent need for new anthelmintic compounds in veterinary medicine.
- To argue that current market conditions are becoming favorable for the development of new anthelmintics.
- To emphasize the importance of resistance management strategies for ensuring product longevity.
Main Methods:
- This study presents a critical analysis of the current landscape of anthelmintic resistance in ruminants.
- It reviews the market dynamics and commercial considerations for new drug development in animal health.
- It synthesizes information on the prevalence of multiple-drug resistance and the scarcity of alternative control methods.
Main Results:
- Anthelmintic resistance is a growing global concern, severely impacting small ruminant production.
- The market for new anthelmintics is expanding due to increasing multi-drug resistance in nematodes.
- Limited non-chemical control options further drive the demand for effective treatments.
Conclusions:
- A new anthelmintic drug is urgently required to address the escalating resistance crisis in small ruminants.
- The market is receptive to new anthelmintic solutions, offering commercial potential for innovation.
- Implementing robust resistance management strategies will be key to maximizing the lifespan and effectiveness of new products.
Related Concept Videos
Anthelminthic Agents
Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...
Antiprotozoal Agents
Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...


